Search

Your search keyword '"Kumada, Hiromitsu"' showing total 2,389 results
Start Over Author "Kumada, Hiromitsu"
2,389 results on '"Kumada, Hiromitsu"'

307. Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks

Author

Suzuki, Fumitaka, Akuta, Norio, Suzuki, Yoshiyuki, Sezaki, Hitomi, Yatsuji, Hiromi, Kawamura, Yusuke, Hosaka, Tetsuya, Kobayashi, Masahiro, Arase, Yasuji, Ikeda, Kenji, Mineta, Rie, Iwasaki, Satomi, Watahiki, Sachiyo, Kobayashi, Mariko, Miyakawa, Yuzo, and Kumada, Hiromitsu

Published
2009
Full Text
View/download PDF

314. A Matched Case-Controlled Study of 48 and 72 Weeks of Peginterferon Plus Ribavirin Combination Therapy in Patients Infected With HCV Genotype 1b in Japan: Amino Acid Substitutions in HCV Core Region as Predictor of Sustained Virological Response

Author

Akuta, Norio, Suzuki, Fumitaka, Hirakawa, Miharu, Kawamura, Yusuke, Yatsuji, Hiromi, Sezaki, Hitomi, Suzuki, Yoshiyuki, Hosaka, Tetsuya, Kobayashi, Masahiro, Kobayashi, Mariko, Saitoh, Satoshi, Arase, Yasuji, Ikeda, Kenji, and Kumada, Hiromitsu

Published
2009
Full Text
View/download PDF

316. Renal safety and biochemical changes for 2 years after switching to tenofovir alafenamide from long‐term other nucleotide analog treatment in patients with chronic hepatitis B.

Author

Hosaka, Tetsuya, Suzuki, Fumitaka, Kobayashi, Masahiro, Fujiyama, Shunichirou, Kawamura, Yusuke, Sezaki, Hitomi, Akuta, Norio, Suzuki, Yoshiyuki, Saitoh, Satoshi, Arase, Yasuji, Ikeda, Kenji, Kobayashi, Mariko, and Kumada, Hiromitsu

Subjects
CHRONIC hepatitis B, TENOFOVIR, GLOMERULAR filtration rate, CHRONIC kidney failure, EPIDERMAL growth factor receptors
Abstract

Background: Long‐term use of nucleotide analogs such as adefovir (ADV) or tenofovir disoproxil fumarate (TDF) may cause renal impairment. Tenofovir alafenamide (TAF) has less systemic exposure than TDF did. The aims were to examine longitudinal changes in renal function and biochemical parameters for 2 years after switching from long‐term ADV and TDF to TAF, and to explore factors associated with improved renal function after TAF in patients with chronic hepatitis B. Methods: The prospective observational cohort study included 306 patients with chronic hepatitis B who underwent switching from long‐term TDF or ADV to TAF. The primary outcome was the changes in estimated glomerular filtration rate (eGFR) after TAF. Results: Among 306 patients, 190 (65.3%) and 106 (34.7%) had chronic kidney disease (CKD) stages 1–2 and 3a–4 at baseline. In patients with CKD stages 3a–4, the mean eGFR significantly increased until week 12 and plateaued from week 12 to year 2 (adjusted slope using linear mixed effect models: +9.01 ml/min/1.73 m2/year until week 12; p < 0.001). In contrast, the mean eGFR plateaued from baseline to year 2 in the CKD stages 1–2 subgroup. Multivariate logistic regression showed that baseline CKD stage ≥3a, steeper decline in eGFR 1 year before TAF, and shorter duration of any nucleotide analog use was significantly associated with ≥10% improvement in eGFR in year 1. Conclusions: Switching from TDF or ADV to TAF resulted in favorable renal safety for 2 years. In CKD stage 3a–4 subgroup, eGFR after TAF was recovered in the first 12 weeks and subsequently stabilized. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

317. Dynamics of Circulating miR-122 Predict Liver Cancer and Mortality in Japanese Patients with Histopathologically Confirmed NAFLD and Severe Fibrosis Stage.

Author

Akuta, Norio, Kawamura, Yusuke, Suzuki, Fumitaka, Saitoh, Satoshi, Arase, Yasuji, Muraishi, Nozomu, Fujiyama, Shunichiro, Sezaki, Hitomi, Hosaka, Tetsuya, Kobayashi, Masahiro, Kobayashi, Mariko, Suzuki, Yoshiyuki, Ikeda, Kenji, and Kumada, Hiromitsu

Subjects
DISEASE progression, LIVER tumors, BIOPSY, FATTY liver, FIBROSIS, SEVERITY of illness index, DESCRIPTIVE statistics, EXTRACELLULAR space, NUCLEIC acids, BLOOD
Abstract

Introduction: It is unclear whether the relationships between changes in fibrosis and circulating microRNA-122 (miR-122) dynamics might influence the prognosis of nonalcoholic fatty liver disease (NAFLD). Methods: This study investigates the impact of serum miR-122 dynamics and histological changes on the incidence of liver cancer and mortality in 81 Japanese NAFLD patients who underwent serial liver biopsies. The median interval between the first and second liver biopsies was 2.9 years. Results: The fibrosis stage scores indicated progression, no change, and improvement (a decrease of one point or more) in 21.0%, 56.8%, and 22.2% of the patients, respectively. There were 64 patients in the high-risk group who had no improvement in stage scores. Among these, the miR-122 levels were significantly lower in 7 patients with liver cancer than those of the 54 patients who had no liver cancer at the second liver biopsy. The cumulative rates of liver cancer were significantly higher in cases with miR-122 ratios <0.5 (serum miR-122 level at second biopsy to that at first biopsy) than those with ratios ≥0.5. The cumulative survival rates in cases with miR-122 ratios <0.5 tended to be lower than those with ratios ≥0.5. Of the 64 high-risk patients, 39 indicated stage 2 or greater (severe fibrosis stage) at the first liver biopsy and also showed similar results of cumulative liver cancer and survival rates. Conclusions: Longitudinal examination of serial liver biopsies indicated that the circulating miR-122 dynamics might be useful in predicting the prognosis for NAFLD patients with severe fibrosis stage and no improvement of the stage scores. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

318. Ultrasensitive Assay for Hepatitis B Core‐Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir.

Author

Hosaka, Tetsuya, Suzuki, Fumitaka, Kobayashi, Mariko, Fujiyama, Shunichiro, Kawamura, Yusuke, Sezaki, Hitomi, Akuta, Norio, Kobayashi, Masahiro, Suzuki, Yoshiyuki, Saitoh, Satoshi, Arase, Yasuji, Ikeda, Kenji, and Kumada, Hiromitsu

Subjects
CHRONIC hepatitis B, HEPATITIS associated antigen, HEPATITIS B, HEPATOCELLULAR carcinoma, CIRCULAR DNA, CELL surface antigens, BIOMARKERS
Abstract

Serum hepatitis B core‐related antigen (HBcrAg) and surface antigen (HBsAg) are surrogate markers of intrahepatic covalently closed circular DNA. The measurement range of the current HBcrAg assay is relatively narrow. Thus, we examined the potential of HBcrAg and HBsAg measured by ultrasensitive assays for predicting hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B treated with entecavir (ETV). We conducted a retrospective cohort study of 180 patients who received ETV for >1 year. All patients had hepatitis B e‐antigen negativity at baseline. Serum HBcrAg and HBsAg levels at baseline and year 1 were measured in all patients by ultrasensitive assays using immunoassay for total antigen including complex by pretreatment (iTACT) technology. During the median follow‐up of 11.0 years, 22 patients developed HCC (11.8/1,000 person‐years). Baseline HBsAg levels were not associated with HCC development during ETV treatment. However, high HBcrAg levels at baseline and at year 1 were significantly associated with HCC development (log‐rank test; P < 0.001). In 110 patients (61.1%) with ≥4.0 log U/mL at baseline (high HBcrAg cohort), HBcrAg declined to ≤2.9 log U/mL at year 1 in 25 patients (22.7%). The adjusted hazard ratio for HCC incidence was significantly lower in patients with HBcrAg ≤2.9 log U/mL at year 1 than in those in the high HBcrAg cohort. Conclusion: Measurement of HBcrAg by ultrasensitive assay has better potential for predicting HCC during antiviral treatment than the current HBcrAg assay. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

320. Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma

Author

Hoshida, Yujin, Villanueva, Augusto, Kobayashi, Masahiro, Peix, Judit, Chiang, Derek Y., Camargo, Amy, Gupta, Supriya, Moore, Jamie, Wrobel, Matthew J., Lerner, Jim, Reich, Michael, Chan, Jennifer A., Glickman, Jonathan N., Ikeda, Kenji, Hashimoto, Masaji, Watanabe, Goro, Daidone, Maria G., Roayaie, Sasan, Schwartz, Myron, Thung, Swan, Salvesen, Helga B., Gabriel, Stacey, Mazzaferro, Vincenzo, Bruix, Jordi, Friedman, Scott L., Kumada, Hiromitsu, Llovet, Josep M., and Golub, Todd R.

Published
2008
Full Text
View/download PDF

332. (18)F-Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma as a Useful Predictor of an Extremely Rapid Response to Lenvatinib

Author

Kawamura, Yusuke, Kobayashi, Masahiro, Shindoh, Junichi, Kobayashi, Yuta, Kasuya, Kayoko, Sano, Tomoya, Fujiyama, Shunichiro, Hosaka, Tetsuya, Saitoh, Satoshi, Sezaki, Hitomi, Akuta, Norio, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Ikeda, Kenji, Arase, Yasuji, Hashimoto, Masaji, and Kumada, Hiromitsu

Subjects
Original Paper
Abstract

BACKGROUND AND AIMS: This study aimed to identify the utility of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) as a predictor of the response of hepatocellular carcinoma (HCC) to lenvatinib. METHODS: We evaluated 28 consecutive patients with HCC diagnosed by dynamic CT or magnetic resonance imaging combined with 18F-FDG-PET/CT. The tumor-to-normal liver standardized uptake value ratio (TLR) of the target tumor was measured before treatment using 18F-FDG-PET/CT, with a TLR ≥2 classified as a high potential for malignant HCC. The treatment response was evaluated 2 weeks after the initiation of lenvatinib using modified Response Evaluation Criteria in Solid Tumors. RESULTS: Of the 28 patients, 12 (43%) presented with a TLR ≥2. Evaluation of the treatment response at 2 weeks in these 12 patients revealed that 2 (17%) exhibited a complete response, 8 (67%) a partial response, 2 (17%) stable disease, and none with progressive disease. Therefore, 10 of the 12 patients (83%) experienced an objective response to lenvatinib. On the other hand, 7 of the 16 patients with a TLR

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results